Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People

PHASE3CompletedINTERVENTIONAL
Enrollment

370

Participants

Timeline

Start Date

October 15, 2009

Primary Completion Date

May 27, 2010

Study Completion Date

May 27, 2010

Conditions
Influenza
Interventions
BIOLOGICAL

GSK investigational vaccine 2186877A

Single dose, intramuscular injection

BIOLOGICAL

FluarixTM

Single dose, intramuscular injection

Trial Locations (24)

10435

GSK Investigational Site, Berlin

12627

GSK Investigational Site, Berlin

13347

GSK Investigational Site, Berlin

22335

GSK Investigational Site, Hamburg

22415

GSK Investigational Site, Hamburg

39112

GSK Investigational Site, Magdeburg

39326

GSK Investigational Site, Wolmirstedt

45359

GSK Investigational Site, Essen

51069

GSK Investigational Site, Cologne

55131

GSK Investigational Site, Mainz

55624

GSK Investigational Site, Rhaunen

68161

GSK Investigational Site, Mannheim

69469

GSK Investigational Site, Weinheim

73635

GSK Investigational Site, Rudersberg

74363

GSK Investigational Site, Güglingen

86150

GSK Investigational Site, Augsburg

01067

GSK Investigational Site, Dresden

01705

GSK Investigational Site, Freital

04103

GSK Investigational Site, Leipzig

3011 AA

GSK Investigational Site, Rotterdam

3011 EN

GSK Investigational Site, Rotterdam

SE-631 88

GSK Investigational Site, Eskilstuna

SE-371 41

GSK Investigational Site, Karlskrona

SE-751 85

GSK Investigational Site, Uppsala

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY